Cardura Advisory Cmte. To Discuss Limiting Hypertension Use To Second-Line
FDA's Cardiovascular & Renal Drugs Advisory Committee is expected to discuss limiting Pfizer's Cardura (doxazosin) to second-line treatment for hypertension May 24.
FDA's Cardiovascular & Renal Drugs Advisory Committee is expected to discuss limiting Pfizer's Cardura (doxazosin) to second-line treatment for hypertension May 24.